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This article contains mass spectrometry (MS) data investigating small
molecule changes as an effect of a triple peroxisome proliferator-
activated receptor (PPAR-pan) agonist GW625019 in the liver as
described in the manuscript (Ament et al., 2016) [1]. Samples were
measured using gas chromatography-mass spectrometry (GC–MS)
for total fatty acid content, and liquid chromatography-mass spec-
trometry (LC–MS) to measure intact lipids, carnitines and selected
aqueous metabolites and eicosanoids. Data ﬁles comprise of Excel
(Microsoft, WA, USA) spreadsheets of identiﬁedmetabolites and their
area ratio values for total fatty acids, carnitines, aqueous metabolites,
and eicosanoids where the intensity of the analytes were normalised
to the intensity of the internal standard. In the case of open proﬁling
intact lipid data, the Excel ﬁle contains area ratio values of retention
time and mass to charge ratio pairs; again, the area ratio values were
calculated by normalising to the intensity of the internal standard. It
should be noted that several metabolic changes are potentially
indirect (secondary, tertiary and ensuing changes).
& 2016 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
/j.freeradbiomed.2015.11.033
(J.L. Grifﬁn).
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Dubject area Biochemistry
ore speciﬁc sub-
ject areaMetabolomicsype of data Mass Spectrometry data summarized in Excel spreadsheets
ow data was
acquiredGC-MS of total fatty acids: Trace GC Ultra coupled to a DSQ II
LC-MS of intact lipids: Waters Xevo G2 (Q-ToF) mass spectrometer coupled to an
Acquity UPLC.
LC-MS of acyl-carnitines: AB Sciex 5500 Qtrap mass spectrometer coupled to an
Acquity UPLC.
LC-MS of aqueous metabolites: AB Sciex 5500 Qtrap mass spectrometer coupled
to a SIL20-A LC system
LC-MS of eicosanoid metabolites: AB Sciex 4000 Qtrap mass spectrometer cou-
pled to an Acquity UPLC.ata format Peak picked and normalised to relevant internal standard and wet tissue weight
xperimental
factorsMetabolites were extracted from liver tissue samples using a modiﬁed Bligh and
Dyer procedure using chloroform, methanol and waterxperimental
featuresLiver metabolite response to different doses of PPAR-pan agonistata source
locationCambridge, United Kingdomata accessibility Data is within this article and for the carnitine and targeted aqueous metabo-
lites the data is accessible through the MetaboLights repository under study
numbers MTBLS278 (eicosanoid data) and MTBLS303 (carnitine and aqueous
metabolites).Value of the data
 These data provide a broad survey of rat liver metabolite changes due to PPAR-pan agonist
treatment.
 The different datasets can be used to explore challenges of data merging and integration across
analysis platforms.
 The study has both a dose response and drug recovery aspect allowing others to model these types
of data.1. Data
This article contains mass spectrometry data of small molecules, including open proﬁling assays
for total fatty acids (GC–MS) and intact lipids (LC–MS) as well as targeted LC–MS assays for the
detection of a range of carnitines, aqueous metabolites and eicosanoids [1]. The carnitine, aqueous
and eicosanoid datasets are available in raw data form through MetaboLights (MTBLS278, MTBLS303).2. Experimental design, materials and methods
2.1. Study design
All animal studies were ethically reviewed and carried out in accordance with Animals (Scientiﬁc
Procedures) Act 1986 and the GSK Policy on the Care, Welfare and Treatment of Animals. GW625019,
a PPAR-pan activator was administered to male Sprague–Dawley rats (Crl:CD (SD) strain), 12 animals
Table 1
Study design.
Group description Dose (mg/kg/day) Animal number Recovery animals
Control 0 1–12 13–18
Low 30 19–30 
Intermediate 1 100 31–42 
Intermediate 2 300 43–54 55–60
High 1000 61–72 73–78
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group of animals (6 per group) were kept for a 4 week treatment free period in the control, inter-
mediate 2 (300 mg/kg/day) and high (1000 mg/kg/day) dose groups (Table 1).
All samples were analysed for total fatty acid, intact lipids, carnitine and aqueous metabolite
content. Eicosanoids were measured from a subset of the samples including the control, intermediate
2 (300 mg/kg/day) and high (1000 mg/kg/day) dose groups.
2.2. Sampling
Tissue samples were collected following an overdose of anaesthetic (halothane Ph. Eur. Vapour).
Samples of the liver were immediately removed, weighed, and sections snap-frozen in liquid nitro-
gen. Samples were maintained at 80 °C until further analysis.
2.3. Extraction of total fatty acids, intact lipids, carnitines and aqueous metabolites
Methanol: chloroform solution (2:1, 600 mL) was added to approximately 50 mg of frozen tissue
and homogenised with a tissue lyser. Chloroform and water (200 mL each) was added, samples were
sonicated for 15 min and centrifuged (13,500 rpm, 20 min). The resulting aqueous and organic layers
were separated and the extraction procedure was repeated. Samples were dried under nitrogen and
processed for mass spectrometry.
2.4. GC–MS analysis of fatty acid methyl esters (FAMEs)
Organic fractions were reconstituted in 1 mL of methanol:chloroform 2:1 and a ﬁfth of each
sample (200 mL) was dried under nitrogen. Chloroform:methanol (1:1, 100 μl), boron triﬂuoride in
methanol (10%, 125 μl) and 150 mL D-25-tridecanoic acid (200 mM in chloroform) were added to the
dried extracts. Samples were vortex mixed and heated to 80 °C for 90 min. After cooling, 300 mL water
and 600 mL hexane were added, samples were vortex mixed, the lower aqueous layer was discarded
and the remaining organic layer dried under nitrogen. The samples were reconstituted in 150 μl
hexane and transferred to autosampler vials prior to analysis using a Trace GC Ultra coupled to a DSQ
II single-quadrupole mass spectrometer (Thermo Scientiﬁc, Hemel Hempstead, Hertfordshire). Sam-
ples were injected onto a Zebron™ ZB-WAX column (100% polyethylene glycol 30 m0.25 mm ID,
0.25 mm ﬁlm thickness). The injector temperature was 230 °C and the ﬂow rate of helium was 1.2 mL/
min. The columnwas held at 60 °C for 2 min, after which the temperature was increased to 150 °C at a
rate of 15 °C/min, and ﬁnally increased to 240 °C at a rate of 2.5 °C/min. The transfer line temperature
was maintained at 240 °C, while the ion source was at 250 °C, operating at 70 eV for electron ioni-
sation (EI). The detector was initiated after 240 s, and full scan spectra were collected over a range of
50–650m/z [2,3]. GC–MS chromatograms were processed using Xcalibur™ (version 2.0; Thermo
Electron, Waltham, Massachusetts) (Supplementary Data 1).
2.5. Open proﬁling LC–MS/MS analysis of intact lipids
A 10 mL aliquot, comprising one hundredth of the organic fraction, was diluted into 90 mL of
methanol-chloroform (2:1) containing 20 mM 1,2-diheptadecanoyl-sn-glycero-3-phosphocholine (PC
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G2 Quadrupole Time of Flight (QToF) mass spectrometer with a Z-spray electrospray source (Waters
Ltd., Elstree, Hertfordshire, UK) coupled to an ACQUITY Ultra Performance Liquid Chromatography
(UPLC) system with an Acquity CSH C18, 1.7 mm (2.1100 mm) column (Waters Ltd., Elstree, Hert-
fordshire, UK). Mobile phase A consisted of 10 mM ammonium formate in acetonitrile: water (6:4),
whilst mobile phase B contained 10 mM ammonium formate in isopropanol: acetonitrile (9:1). The
concentration of mobile phase B was increased from 40% to 100% over 18 min, then equilibrated to
40% B for 2 min at a ﬂow rate of 0.4 mL/min. The electrospray source was operated in positive ion
mode with the source temperature set at 80 °C and a cone gas ﬂow of 100 L/h. The desolvation gas
temperature was 250 °C and the nebuliser gas ﬂow rate was set at 700 L/h. The capillary voltage was
3 kV and the cone voltage 50 V. Mass spectrometric data were collected from 50 to 1200m/z in
proﬁling scan mode. Data were processed using MarkerLynx™ within the software suite MassLynx™
(version 4.1) by Waters Ltd. (Elstree, Hertfordshire, UK). Collection Parameters were set with a mass
window of 0.05 Da and retention time window of 0.2 min (Supplementary Data 2).
2.6. Analysis of acyl-carnitines
One hundred microliters of internal standard solution mix (1.63 mM [D9] free carnitine, 0.3 mM
[D3] acetyl carnitine, 0.06 mM [D3] propionyl-carnitine, 0.06 mM [D3] butyryl-carnitine, 0.06 mM [D9]
isovarelyl-carnitine, 0.06 mM [D3] octanoyl-carnitine, 0.06 mM [D9] myristoyl-carnitine, and 0.12 mM
[D3] palmitoyl-carnitine, Cambridge Isotope Laboratories, Andover, MA, USA) was added to 40 mL of
the organic fraction of the methanol: chloroform extraction and the resulting mixture were dried
down under nitrogen and derivatised with 100 mL of 3 M butanolic-HCl (Sigma-Aldrich, Louis, Mis-
souri, USA). Samples were evaporated under nitrogen, re-constituted and sonicated in 4:1 acetoni-
trile: 0.1% formic acid in water before transferring them to autosampler vials. Samples were analysed
using an AB Sciex 5500 QTRAP mass spectrometer (AB Sciex UK Limited, Warrington, Cheshire)
coupled to an Acquity UPLC system. Mobile phase A consisted of 0.1% formic acid in water, while
mobile phase B was acetonitrile. Two microliters of each sample was injected onto a Synergi Polar RP
phenyl ether column (100 mm2.1 mm, 2.5 mm) supplied by Phenomenex (Macclesﬁeld, Cheshire,Table 2
A list of mass to charge (m/z) ratios showing [MH] values for each measured aqueous metabolite and the corresponding
fragment ion after collision-induced dissociation (CID). Q1 denotes the parent ions, whereas Q3 denotes the fragment ions.
Analyte Q1 Q3 Analyte Q1 Q3
3-PG 187.0 105.0 GSH 308.1 179.0
Acetyl-CoA 810.0 303.2 GSSG 613.1 355.0
Adenine 136.0 119.0 GTP 523.9 152.0
Adenosine 268.1 136.1 Guanine 152.0 134.9
ADP 428.0 136.0 Guanosine 284.1 152.1
AMP 348.0 136.0 Malonyl-CoA 854.0 347.1
ATP 508.0 136.0 Methyl-cytosine 126.0 109.1
cAMP 330.1 136.1 NAD 664.0 427.9
CDP-choline 489.1 184.1 Oxo-methionine 165.0 105.0
cGMP 346.1 152.1 PCr 212.1 177.1
CMP 324.1 112.0 PEP 169.1 150.9
Cytidine 244.1 112.0 SAH 385.1 136.1
Cytosine 112.0 95.0 SAM 399.0 250.1
FAD 786.1 348.0 UMP 325.1 96.9
GDP 444.0 152.0 Uracil 112.9 70.1
GMP 364.2 152.1 Uridine 245.1 112.9
Abbreviations: 3PG, 3-phosphoglycerate; ADP, adenosine diphosphate; AMP, adenosine monophosphate; ATP, adenosine tri-
phosphate; cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; CMP, cytidine monophosphate;
FAD, ﬂavin adenine dinucleotide; GDP, guanosine diphosphate; GMP, guanosine monophosphate; GSH, glutathione; GSSG,
oxidised glutathione; GTP, guanosine triphosphate; NAD, nicotineamide adenine dinucleotide; PCr, phosphocreatine; PEP,
phosphoenolpyruvate; SAH, S-adenosyl-homocysteine; SAM, S-adenosyl-methionine; UMP, uridine monophosphate.
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gradient was then held at 100% B for 5 min, after which it was returned to the re-equilibration level of
30% B for 2 min. A ﬂow rate of 0.5 mL/min was used throughout [4]. Data were analysed using the
Quantitation Wizard within Analyst™ version 1.6 by AB Sciex Ltd. (Warrington, Cheshire, UK)
(Supplementary Data 3).
2.7. Targeted analysis of aqueous metabolites
The entire aqueous fraction was dissolved in 300 ml of 70:30 acetonitrile: water containing 20 mM
universally 13C- and 15N- labelled glutamate. Samples were vortex mixed, sonicated, centrifuged,
(17,000g, 5 min) pipetted into auto sampler vials and analysed using an AB Sciex 5500 Qtrap mass
spectrometer (AB Sciex UK Limited, Warrington, Cheshire) coupled to a SIL20-A LC system (Shimadzu
Corp., Kyoto, Japan). Mobile phase A consisted of 100 mM ammonium acetate, mobile phase B was
acetonitrile, and the ﬂow rate was 0.3 mL/min. Two microliters of each sample was injected, and
analytes separated using a 100 mm ZIC-HILIC column with 2.1 mm ID and 3.5 mm particle size
(Sequant, Umeå, Sweden). A linear gradient was used, starting at 20% A for 2 min, followed by an
increase to 50% A over 10 min, and ﬁnally a 3 min re-equilibration. Metabolites of interest were
measured in positive ionisation mode with unscheduled multiple reaction monitoring events (MRMs)
(Table 2), using a source temperature of 500 °C, an ion spray voltage of 4.5 kV and a dwell time of
50 ms. Peaks were integrated by the Quantitation Wizard within Analyst™ version 1.6 by AB Sciex
Ltd. (Warrington, Cheshire, UK) and normalised against wet tissue weight and to the intensity of the
internal standards (Supplementary Data 4).
2.8. Extraction and analysis of eicosanoids
Eicosanoids were extracted using solid phase extraction (SPE) Waters Oasis-HLB cartridges
(Waters Ltd., Elstree, Hertfordshire, UK) [4]. SPE columns were washed with ethyl acetate (2 mL),
methanol (22 mL), and 15% methanol with 0.1% acetic acid (2 mL). Approximately 100 mg liver
tissue samples were homogenised on a TissueLyser (Qiagen Ltd., Manchester, UK; 10 min at 30 Hz) in
1.5 mL 15% methanol with 0.1% acetic acid. The samples were centrifuged (17,000g, 2 min) and the
supernatant loaded onto the SPE columns. Cartridges were washed with 1 mL 15% methanol with 0.1%
acetic acid. Analytes of interest were eluted with 0.5 mL of methanol followed by 1 mL of ethyl acetate
and immediately dried under nitrogen. Samples were ﬁnally reconstituted in 40 mL methanol con-
taining 70 nM PGE2-d4 internal standard and transferred to autosampler vials. Analysis was per-
formed using a 4000 QTRAP mass spectrometer (AB Sciex UK Limited, Warrington, Cheshire) coupledTable 3
Eicosanoid method gradient.
Analysis
Column C18 Luna column (Phenomenex)
column dimensions 150 mm2 mm, 3 mm
Liquid chromatograph Waters Acquity
ﬂow rate 0.4 mL/min
mobile phase A 0.1% acetic acid
mobile phase B 0.1% acetic acid
in acetonitrile: methanol (80:20)
Gradient 0 min 15% B
1.5 min 30% B
10.5 min 60% B
16 min 80% B
19 min 100% B
19.1 min 15% B
21 min 15% B
Table 4
A list of mass to charge (m/z) ratios showing [MH] values for each measured eicosanoid and the corresponding fragment ion
after collision-induced dissociation (CID). Q1 denotes the parent ions, whereas Q3 denotes the fragment ions.
Analyte Q1 Q3 Analyte Q1 Q3
11(12)-EET 319.2 167 8,9-DHET 337.2 127.1
11,12,15-THET 353.2 167.1 8-HETE 319.2 301.2
11,12-DHET 337.2 167.1 8-iso-PGE2 351 271
11-HEPE 317 169 8-isoPGF2α 353.1 193.2
11-HETE 319.18 166.9 9(10)-EpOME 295.2 171.1
12(13)-EpOME 295.2 195.2 9,10,13-TriHOME 329.2 171.1
12,13-DHOME 313.2 183.2 9,10-DHOME 313.2 201.2
12-HEPE 317.17 179 9,12,13-TriHOME 329.2 211.1
12-HETE 319.2 179.2 9-HODE 295.2 171
13-HDoHE 343.13 193 9-oxo-ODE 292.2 185.1
13-HODE 295.2 195 AA 303.3 259.1
13-oxo-ODE 239.2 113 DHEA 327.2 283.1
14(15)-EET 319.2 219.3 DGLA 305.19 58.8
14,15-DHET 337.19 206.9 Lipoxin A4 351.2 115.2
15-deoxyPGJ2 315.2 271.3 LTB4 335.2 195.1
15-HETE 319.2 301.4 PGB2 333.069 59
15-oxo-EET 317.2 113.1 PGD2 351.2 271.3
19-HETE 319.2 275.1 PGE2 351.2 271.3
20-HETE 319.2 275.2 PGE2-d4 355.3 275.3
5(6)-EET 319.2 191 PGF2α 353.2 309.3
5,6-DHET 337.2 145.1 THF diols 353.2 167.1
5-oxo-EET 317.2 273.2 TXB2 369.2 169.1
Abbreviations: AA, arachidonic acid; DGLA, dihomo-γ-linolenic acid; DHEA, docosahexaenoic acid; DHET, dihydroxyeicosa-
trienoic acid; DHOME, dihydroxyoctadecenoic acid; EET, epoxyeicosatrienoic acid; HDoHE, hydroxydocosahexaenoic acid;
HEPE, hydroxyeicosapentaenoic acid; HETE, hydroxyeicosatetraenoic acid; HODE, hydroxyoctadienoic acid; LT, leukotriene;
ODE, octadienoic acid, PG, prostaglandin; THET, trihydroxyeicosatetraenoic acid; THF, tetrahydrofuran; TX, thromboxane.
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The autosampler was maintained at 4 °C, LC separation was achieved using a Luna, 3 μm particle size,
1502 mm column (Phenomenex Macclesﬁeld, Cheshire, UK). The gradient of mobile phase A (0.1%
acetic acid in water) and B (0.1% acetic acid in acetonitrile: methanol 80:20) is detailed in Table 3. The
ﬂow rate was held at 0.4 mL/min. Metabolites of interest were measured in negative ionisation mode
with unscheduled multiple reaction monitoring events (MRMs) (Table 4). Peaks were integrated by
the Quantitation Wizard within Analyst™ version 1.6 by AB Sciex Ltd. (Warrington, Cheshire, UK)
(Supplementary Data 5).Acknowledgements
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